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Programmed death-1 (PD-1) was shown to deliver an inhibitory signal after binding to its ligands, PD-L1 (B7-H1) or PD-L2
(B7-DC). Recently, up-regulated expression of PD-1 molecule and/or its ligands was demonstrated in human diseases including
rheumatoid arthritis and inﬂammatory colitis. The study aimed to investigate the expression and function of PD-1 and PD-1
ligandsoncirculatingTcells,Bcellsandmonocytesfrompatientwithsystemiclupuserythematosus(SLE).Theresultsshowedthat
patients with SLE had signiﬁcantly increased percentages of PD-1-expressing CD3+Tc e l l sa n dC D 1 9 +B cells, PD-L1-expressing
CD19+B cells and PD-L2-expressing CD14+B monocytes. In selected SLE patients and normal subjects, functional study of PD-1/
PD-1 ligands pathway on the production of cytokines by stimulated PBMC was examined. Blockages of PD-1 or PD-1 ligands
substantially increased the production of IL-2, IFN-γ and IL-10, the amplitude of increase roughly ranged from one to three times.
There were no signiﬁcant diﬀerences of the enhancing eﬀects on cytokine production by blockage of PD-1/PDL pathway between
SLE patients and normal subjects. The study indicates that there are no intrinsically defective expression and function of PD-1 and
PD-1 ligands on PBMC in patients with SLE.
Copyright © 2009 Ming-Fei Liu et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Programmed death-1 (PD-1) is a novel member of CD28
family. PD-1 was shown to deliver a negative signal after
binding to either of its two ligands, PD-L1 (B7-H1) or PD-
L2 (B7-DC) in immune responses [1–4]. Meanwhile, PD-
1 and its ligands have been reported to play an important
role in the etiopathogenesis of murine autoimmune dis-
eases. Spontaneous autoimmune diseases including lupus-
like glomerulonephritis, arthritis, and fatal autoimmune
dilated cardiomyopathy developed in PD-1 deﬁcient mice of
diﬀerent genetic backgrounds [5–7]. In addition, blockade
of PD-1/PD-L pathway could exaggerate or accelerate the
development of autoimmune diseases such as diabetes
in prediabetic NOD mice and experimental autoimmune
encephalitis [8, 9]. Recently, up-regulated expression of PD-
1 molecule and/or its ligands was demonstrated in human
diseases including rheumatoid arthritis (RA) and inﬂam-
matory colitis, indicating that PD-1 and PD-1 ligands were
actively participating in the pathogenetic process in human
autoimmunediseases[10,11].Systemiclupuserythematosus
(SLE)isaprototypeofhumansystemicautoimmunedisease,
characterized by dysregulated activation of both T and
B lymphocytes and development of many autoantibodies.
Accordingly, PD-1 and PD-1 ligands may play a critical role
in the pathogenesis of SLE. The present study thus aimed to
investigate the expression and function of PD-1 and its two
ligandsonperipheralmononuclearcells(PBMCs)inpatients
with SLE.
2. Patients andMethods
2.1. Patients. Twenty-eight patients who fulﬁlled at least 4
criteria for the diagnosis of SLE set by the American College
of Rheumatology [12] were enrolled in the study. They
include 26 females and 2 males. All enrolled patients were
not taking corticosteroid and immunosuppressant agents for2 Journal of Biomedicine and Biotechnology
more than 4 weeks prior to the study. 26 young healthy
females were used as a control group. Their peripheral
blood was drawn, and PBMC were immediately isolated for
ﬂowcytometric analysis and in vitro culture.
2.2. Measurement of PD-1 and PD-1 Ligands Expression by
Flowcytometry. Flowcytometry with dual staining was per-
formed using ﬂuorescece-conjugatd MAbs including FITC-
conjugated anti-CD3, anti-CD19, and anti-CD14 (BD Bio-
sciences, Sna Diego CA, USA) and PE-conjugated anti-PD-
1, anti-PDL1, and anti-PDL2 (MIH clones, e Bioscience, Sna
Diego, CA, USA). Brieﬂy, PBMC were prepared from fresh
heparinized blood using Ficoll-Hypaque density gradient
separation and adjusted to 5 × 106 cells/mL. Two hundred
microliters of cell suspension were incubated simultane-
ously with 20μL FITC-conjugated MAb and 20μLP E -
conjugated MAb in diﬀerent combinations on ice in the
dark for 30 minutes. Cells incubated with FITC- and PE-
conjugated mouse IgG were used as isotype controls. The
stained cells were analyzed with a FACSCalibur (Becton
Dickinson)ﬂowcytometerandassociatedsoftwareprograms
(CELLQuest).
2.3. Cell Culture and Stimulation. In selected SLE patients
and normal individuals, their PBMCs (300μL) at the
concentration of 1 × 106 cells/mL were cultured in 96-
well microtiter plates under the stimulation with PMA
(5ng/mL) plus Ionomycin (1μg/mL). For blocking PD-
1/PD-1 ligands interaction, we added MAb against PD-1
(MIH4 clone) or PD-L1 (MIH1 clone) or PD-L2 (MIH18
clone) in the cultured cell system. These were functional
gradepuriﬁedantihumanMAbs.Theirendotoxinlevelswere
all less than 0.001ng/μg antibody as determined by the
LAL assay. The diﬀerent groups include addition of anti-
PD-1 MAb (1μg/well), anti-PD-L1 MAb (1μg/well), anti-
PD-L2 MAb (0.5μg/well), or anti-PD-L1 plus anti-PD-L2.
After 48 hours’ culture, the supernatants were collected, and
cytokinesincludingIFN-γ,IL-2,IL-4,andIL-10wereassayed
by ELISA kits.
2.4. Assay of Cytokines by ELISA. The concentrations of
diﬀerent cytokines in cultured supernatants were measured
by commercially available ELISA kits (Bender MedSystems,
Vienna, Austria). The assay employed the quantitative sand-
wich enzyme immunoassay technique and was performed
as manufacturer’s instruction. The principle of the test
was brieﬂy described below. Standard or samples were
added to react with speciﬁc anticytokine MAb precoated
onto a microplate for 2 hours at room temperature. After
washing, horseradish peroxidase-conjugated polyclonal anti-
bodies against cytokines were added to react with the bound
cytokines for 1 hour. Then, substrate solution was added
and incubated for 20 minutes, followed by addition of stop
solution. The optical density of each well was immediately
determined by microplate reader set to wavelength 450nm.
The concentrations of cytokines in each sample were calcu-
lated from the standard curves.
2.5. Statistics. Fisher’s LSD method was applied to compare
the levels of PD-1 and PD-1 ligands-expressing cells between
SLE and normal controls. Wilcoxon rank sum test was used
to compare the increase percentages of cytokine production
between patients with SLE and normal subjects.
3. Results
3.1. Expression of PD-1/PD-1 Ligands on PBMC. The expres-
sion of PD-1 and its two ligands on freshly prepared PBMC
from 26 normal controls and 28 patients with SLE were
shown in Table 1. One representative FACS Dot-plot data of
PD-1andPD-1ligandsonTcells,Bcells,andmonocyteswas
depicted in Figure 1. In normal controls, PD-1 was barely
detectable on T cells (<1%). Only a very minority of B
cells (mean 2.14%) and monocytes (mean 5.78%) expressed
a low level of PD-1. In contrast, PD-L1 expression was
readily detected on T cells, B cells, and monocytes. Almost
all monocytes (mean 96.66%) expressed PD-L1. Diﬀerent to
PD-L1, PD-L2 expression was mainly noted on monocytes
(mean 72.12%) with only a minority of T cells and B cells
(mean <4%) expressed PD-L2. Similar expression pattern of
PD-1 and PD-1 ligands on each mononuclear cell subset was
also observed in patients with SLE.
Compared with normal controls, patients with SLE
had signiﬁcantly increased percentages of PD-1-expressing
CD3+Tc e l l s( 1 .51 ± 1.12% versus 0.64 ± 0.53%, P<. 001)
and PD-1-expressing CD19+Bc e l l s( 5 .11 ± 3.91% versus
2.14 ± 1.67%, P<. 005). Regarding PD-1 ligands, SLE
patients had more PD-L1-expressing CD19+B cells (20.59 ±
10.24% versus 13.21 ± 1.67%, P<. 005) and PD-L2-
expressing CD14+monocytes (84.78±12.82% versus 72.12±
26.92%, P<. 005) than normal controls. Despite slightly
increased frequencies of PD-1 and PD-1 ligands expression
in some cell populations from SLE patients, the mean
ﬂuorescence intensities of PD-1 and PD-1 ligands expression
on the positive cells were not signiﬁcantly diﬀerent between
patientswithSLEandnormalcontrols(datanotshown).The
result suggests that the expression of PD-1/PD-1 ligands was
not impaired in human SLE.
3.2. Eﬀects of Blocking PD-1/PD-1 Ligands Pathway on
Cytokines Production by Stimulated PBMC In Vitro.
Cytokines are considered to play an important role in
the pathogenesis of SLE. We thus designed to investigate
the functional eﬀects of blocking PD-1 or PD-1 ligands
on the production of various cytokines produced by in
vitro cultured PBMC. The cytokines examined in the study
included Th1-derived cytokines (IL-2 and IFN-γ)a n d
Th2-derived cytokines (IL-4, IL-10). In selected patients and
normal individuals, 8 in each, their freshly prepared PBMCs
were cultured and stimulated with PMA plus ionomycin
in the absence or presence of anti-PD-1 MAb, anti-PD-L1
MAb, anti-PD-L2 MAb, or anti-PD-L1 plus anti-PD-L2
MAbs. We found that blockage of either PD-1 or PD-1
ligands substantially increased the production of IL-2, IFN-
γ, and IL-10 in all cases of PBMC from both SLE and normal
individuals but has no any eﬀect on IL-4. As expected, theJournal of Biomedicine and Biotechnology 3
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Figure 1: One representative FACS Dot-plot data of PD-1, PD-L1, and PD-L2 on CD3+T cells (a), CD19+B cells (b), and CD14+monocytes
(c).
concentration of cytokines produced by stimulated PBMC
in vitro varied widely among diﬀerent SLE patients and
normal controls. For further comparison between SLE
and normal subjects, the amplitudes of enhancement in
cytokine production were expressed as percentages of
increase, which was calculated by the increased amount
of cytokine in the presence of blocking Ab divided by
baseline cytokine concentration in isotype IgG control.
Among the experiments, a few samples of stimulated PBMC
had no detectable baseline cytokine. They were omitted in
comparison due to diﬃculty in calculation of percentages
of increase. As shown in Table 2, blockage of PD-1/PD-1
liagnds pathway greatly increased production of IFN-γ,
which ranged averagely from 134% to 160% in normal
controls and from 153% to 203% in SLE. It seemed that
the enhancement of IFN-γ production was stronger in SLE.
However,thediﬀerencesdidnotreachstatisticalsigniﬁcance.
S i m i l a rt oI F N - γ, IL-2 levels were much increased, in which
the amplitudes of increased percentages ranged averagely
from 156% to 243% in normal control and from 189% to
397% in patient with SLE (Table 3). The enhancing eﬀect on
IL-10 was readily seen too, which ranged averagely from 97%
to 126% in normal controls and from 73% to 132% in SLE
(Table 4). There were also no signiﬁcant diﬀerences in the
increased production of IL-2 and IL-10 between SLE patients
and normal subjects. In addition, it appeared that anti-PD-1
possessed similar eﬀects as anti-PD-L1 or anti-PD-L2.
Meanwhile, there were no synergic eﬀects by anti-PD-L14 Journal of Biomedicine and Biotechnology
Table 1: Comparisons of PD-1 and PD-1 ligands-expressing PBMC between SLE and normal controls.
CD3+Tc e l l s C D 1 9 +Bc e l l s C D 1 4 + Monocytes
Normal (n = 26)
Mean ± SD (%)
SLE (n = 28)
Mean ± SD (%)
Normal (n = 26)
Mean ± SD (%)
SLE (n = 28)
Mean ± SD (%)
Normal (n = 26)
Mean ± SD (%)
SLE (n = 28)
Mean ± SD (%)
PD-1 0.64 ± 0.53 1.52 ± 1.12∗ 2.14 ± 1.67 5.11 ± 3.91∗ 5.78 ± 5.17 7.28 ± 5.79
PD-L1 23.3 ± 8.06 28.01 ± 12.82 13.21 ± 7.66 20.59 ± 10.24∗ 96.66 ± 5.85 96.83 ± 4.24
PD-L2 3.6 ± 2.52 3.79 ± 2.63 3.92 ± 2.95 9.59 ± 19.15 72.12 ± 26.92 84.78 ± 12.82∗
∗indicates statistically signiﬁcant diﬀerence (P<. 05).
Table 2: Enhancement on IFN-γ production by blockage of PD-1 or PD-1 ligands.
Blocking Abs Normal (n = 7)
Mean ± SD (%)∗
SLE (n = 6)
Mean ± SD (%)
P value
Anti-PD-1 156 ± 270 294 ± 658 .731
Anti-PDL1 243 ± 174 271 ± 623 .836
Anti-PDL2 191 ± 197 397 ± 333 .755
Anti-PDL1+Anti-PDL2 177 ± 156 189 ± 665 .876
∗These percentages refer to change over baseline of IgG-treated PBMCs.
plus anti-PD-L2 compared with either alone. There was no
any eﬀect on IL-4 eﬀect by blockage of PD-1/PD-1 ligands
pathway (data not shown).
4. Discussion
The expression of PD-1 and its two ligands on PBMC of
normal individuals and patients with SLE in the present
study was in concordance with previous observation [13–
15]. PD-1 molecule was scarcely expressed on resting T
cells. On the contrary, PD-L1 is constitutively expressed
on T cells, B cells macrophages, and dentritic cells (DCs)
and further upregulated upon activation. In contrast, the
expressionofPD-L2wasregulatedmoretightlyandobserved
on activated macrophage and DCs. The expression of PD-
L1 is also detected on a wide variety of nonlymphoid cells
including vascular endothelial cells, epithelial cells, muscle
cells, hepatocytes, β cells in pancreas, astrocytes in the brain,
as well as at sites of immune privilege including placenta
and eye [16–18]. The expression of PD-L1 on nonlymphoid
tissue was shown to play a crucial role in the control and
maintenance of peripheral T cell tolerance [19].
Compared with normal controls, generally patients with
SLE had increased expression of PD-1 and PD-1 ligands
on T cells, B cells, and monocytes, some of which reached
statistically signiﬁcant diﬀerences, because PD-1 could be
induced on T cells after activation, and increased activated T
cellshavealreadybeenwelldocumentedinpatientswithSLE.
Thus the increased numbers of PD-1-expressing CD3+T
cells in SLE patients could be due to increased numbers of
activated T cells in the periphery of SLE patients. Increased
expression of PD-1 and/or PD-1 ligands had also been
reported in other human autoimmune diseases. Hatachi et
al. demonstrated that PD-1+ T cells were enriched in RA
synovial ﬂuid, and phenotypic analysis suggested that these
cells a unique anergic cell subset [20]. Kobayashi et al.
showed that the expression of PD-1 in salivary lymphocytes
and PD-L1 on ductal and acinar epithelial cells in salivary
glands was enhanced in patients with Sjogren’s syndrome
[21]. However, decreased PD-1 expression on peripheral
CD4+T cells was found in patients with type-1 diabetes in
one study [22]. Probably, PD-1/PD-1 ligands pathway plays
diﬀerent roles in systemic versus organ-speciﬁc autoimmune
diseases. In addition, one study in Lichen planus, a T
cell-mediatedchronicinﬂammatorymucocutaneousdisease,
revealed abundant expression of PD-1 and PD-L1 in inﬁl-
trating T cells and macrophages in the subepithelium and
substantial PD-L1 on kerotinocytes [23].
The inhibitory function of PD-1 molecule was initially
suggested by the studies on PD-1 deﬁcient mice, which
exhibited hyperactivation of the immune system and subse-
quently developed autoimmune diseases. Interestingly, PD-
1 deﬁcient mice developed diﬀerent kinds of autoimmune
diseases depending on the genetic background [5–7]. On
C57BL/6 background, PD-1 deﬁcient mice developed lupus-
like glomerulonephritis and arthritis with deposition of IgG,
and C3 in the glomeruli, whereas PD-1 deﬁcient mice suf-
fered a fatal dilated cardiomyopathy on BALB/c background.
The result of our functional study was in concordance
with the concept of the immunosuppressive role of PD-
1/PD-1 ligands. We showed that blockage of PD-1/PD-1
ligands pathway augmented the production of cytokines in
stimulated PBMC in vitro, with predominant eﬀects on
Th-1 derived cytokines (IL-2 and IFN-γ). Regarding Th-2
cytokines,wealsoobservedenhancingeﬀectonIL-10though
weaker compared with those on IL-2 and IFN-γ.H o w e v e r ,
there was no eﬀect on IL-4 production. Blocking PD-1
molecule or either of the two PD-1 ligands demonstrated
similar eﬀects on the production of various cytokines. As
previously reported, blockage with both anti-PD-L1 and
anti-PD-L2 did not show a signiﬁcantly synergic eﬀect in
our study. The functional study also revealed similar results
between SLE patients and normal controls. ConﬂictingJournal of Biomedicine and Biotechnology 5
Table 3: Enhancement on IL-2 production by blockage of PD-1 or PD-1 ligands.
Blocking Abs Normal (n = 8)
Mean ± SD (%)∗
SLE (n = 8)
Mean ± SD (%)
P value
Anti-PD-1 141 ± 161 193 ± 224 .645
Anti-PDL1 134 ± 201 190 ± 188 .721
Anti-PDL2 160 ± 272 153 ± 216 .879
Anti-PDL1+Anti-PDL2 143 ± 206 203 ± 212 .879
∗These percentages refer to change over baseline of IgG-treated PBMCs.
Table 4: Enhancement on IL-10 production by blockage of PD-1 or PD-1 ligands.
Blocking Abs Normal (n = 8)
Mean ± SD (%)∗
SLE (n = 5)
Mean ± SD (%)
P value
Anti-PD-1 126 ± 230 76 ± 149 .724
Anti-PDL1 97 ± 316 132 ± 232 .943
Anti-PDL2 106 ± 431 73 ± 72 .622
Anti-PDL1+Anti-PDL2 112 ± 349 104 ± 137 .622
∗These percentages refer to change over baseline of IgG-treated PBMCs.
results had been reported in some studies. Ansari et al.
reported that blockade of PD-1 or PD-L1 but not PD-
L2 exaggerated diabetes in prediabetic NOD mice [24].
They observed the expression of PD-L1 but not PD-L2 on
the β cells, which might explain the reason why the anti-
PD-L1 but not anti-PD-L2 antibody exaggerated diabetes,
whereas, Salama et al. observed the acceleration of EAE by
the blockade of PD-1 and PD-L2 but not PD-L1 [25]. Since
PD-L1 but not PD-L2 was highly expressed in the central
nervous system, the expression of ligands in target organs
might not determine the eﬃcient of each blocking antibody.
Blockade of PD-1/PD-L pathway might have an opposite
eﬀect on autoimmune diseases in certain condition. Kanai
et al. examined the eﬀect of blocking antibodies against
PD-L1 and PD-L2 on the colitis model [26]. Antibodies
against PD-L1 but not PD-L2 suppressed the development
of colitis, indicating the costimulatory function of PD-L1
in the inﬂammatory response in the gut. According to the
report by Loke and Allison [27], the expression of PD-
L1 and PD-L2 was diﬀerentially regulated by Th1 and Th2
cytokines. Since the recent analyses using blocking anti-
bodies against PD-L1 and PD-L2 revealed nonoverlapping
functions of these ligands, the diﬀerential regulation of
PD-L1 and PD-L2 expression might have some biological
signiﬁcance.
In conclusion, the present study found that there were no
intrinsically defective expression of PD-1 and PD-1 ligands
on PBMC in patients with SLE. On the contrary, we noted
increased expression of PD-1 and/or its ligands in some
subsets of PBMC from patients with SLE. Since PD-1 and
PD-1 ligands play a role in regulation of both activation and
tolerance of lymphocytes, the ﬁndings of our study most
likely reﬂect the activation status of PBMC in lupus patients
and they do not rule out a defect in tolerance mediated
by PD-1. The exact function of increased PD-1 and PD-
1 ligands in some subsets of PBMC in the pathogenesis of
human SLE needs further study.
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